Staar Surgical Co DEFA14A Filing
Ticker: STAA · Form: DEFA14A · Filed: Dec 11, 2025 · CIK: 718937
| Field | Detail |
|---|---|
| Company | Staar Surgical Co (STAA) |
| Form Type | DEFA14A |
| Filed Date | Dec 11, 2025 |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $30.75 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a DEFA14A filing submitted by Staar Surgical Co (ticker: STAA) to the SEC on Dec 11, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $30.75 (ept Alcon's increased all-cash offer of $30.75 per share - a 74% premium to the 90-day).
How long is this filing?
Staar Surgical Co's DEFA14A filing is 8 pages with approximately 2,325 words. Estimated reading time is 9 minutes.
Where can I view the full DEFA14A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,325 words · 9 min read · ~8 pages · Grade level 13.8 · Accepted 2025-12-11 10:02:03
Key Financial Figures
- $30.75 — ept Alcon's increased all-cash offer of $30.75 per share - a 74% premium to the 90-day
Filing Documents
- d84789ddefa14a.htm (DEFA14A) — 36KB
- g84789g1211111848882.jpg (GRAPHIC) — 3KB
- 0001193125-25-315272.txt ( ) — 42KB
Forward-Looking Statements
Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR's stock pr